Bile acid malabsorption causes urgent, watery diarrhea that looks and feels almost identical to IBS-D. The difference matters because BAM has a specific, testable mechanism and responds to targeted treatment with bile acid sequestrants in 70 to 80 percent of cases. Research estimates that 25 to 30 percent of people currently diagnosed with IBS-D actually have BAM. If you have been living with chronic diarrhea that standard IBS treatments have not fixed, this is one of the first conditions worth investigating.
What Is Bile Acid Malabsorption?
Your liver produces bile acids to help digest fat. After doing their job in the small intestine, about 95 percent of bile acids are reabsorbed in the terminal ileum and recycled back to the liver. This recycling process is called the enterohepatic circulation. In bile acid malabsorption, this recycling fails. Excess bile acids spill into the colon, where they stimulate water secretion and accelerate motility. The result is urgent, watery diarrhea, often with cramping and bloating. The name 'malabsorption' is somewhat misleading for the most common type. In Type 2 BAM, the ileum actually works fine. The problem is that the liver overproduces bile acids, overwhelming the ileum's capacity to reabsorb them. Researchers now believe impaired FGF19 signaling is the mechanism: FGF19 is a hormone released by the ileum that tells the liver to slow down bile acid production. When FGF19 levels are low, the liver keeps producing bile acids without adequate feedback, flooding the system.
The Three Types of BAM
BAM is classified into three types based on the underlying cause. Understanding the type matters because it determines treatment approach and prognosis.
BAM Classification
- Type 1 (ileal): Caused by disease or resection of the terminal ileum. Crohn's disease affecting the ileum is the most common cause. Radiation enteritis and surgical removal of the ileum also fall into this category. The ileum simply cannot reabsorb bile acids because the tissue is damaged or missing.
- Type 2 (idiopathic/primary): The most common type and the one most frequently misdiagnosed as IBS-D. There is no structural ileal disease. The current leading hypothesis is that impaired FGF19 signaling causes the liver to overproduce bile acids, exceeding the ileum's normal reabsorptive capacity. This type accounts for the majority of the 25 to 30 percent of IBS-D patients found to have BAM on testing.
- Type 3 (secondary): Caused by other gastrointestinal conditions that disrupt bile acid metabolism. The most common cause is cholecystectomy (gallbladder removal), which affects 10 to 20 percent of post-surgical patients. Other causes include celiac disease, SIBO, chronic pancreatitis, and diabetes-related autonomic neuropathy affecting gut motility.
How Do the Symptoms Overlap with IBS-D?
The symptom overlap between BAM and IBS-D is extensive. Both conditions cause chronic watery diarrhea, urgency, cramping, and bloating. Both can be intermittent. Both can worsen with stress. This overlap is exactly why BAM goes undetected for years in many patients. However, several clinical features are more suggestive of BAM than IBS-D.
| Feature | More Suggestive of BAM | More Suggestive of IBS-D |
|---|---|---|
| Response to fatty meals | Diarrhea clearly worsens within hours of fatty meals | Symptom triggers are variable and not consistently fat-related |
| Morning pattern | Severe morning diarrhea, often multiple episodes before noon | Symptoms throughout the day without strong morning predominance |
| Stool character | Watery, sometimes yellow or greenish, may have oily appearance | Loose but not always watery, mucus more common |
| Response to sequestrants | Dramatic improvement within days of starting cholestyramine | No significant change on bile acid sequestrants |
| Surgical history | Symptoms started or worsened after cholecystectomy or ileal surgery | No clear surgical trigger |
| Nocturnal symptoms | Can occur, particularly with severe BAM | Less common in functional IBS |
None of these features alone confirms BAM, and there is no symptom that is exclusive to one condition. But the combination of fat-triggered diarrhea, morning predominance, and watery (rather than just loose) stools should prompt testing. A history of gallbladder removal is an especially strong signal: if diarrhea started or worsened after cholecystectomy, Type 3 BAM should be the working hypothesis until testing says otherwise.
Why Is Type 2 BAM So Often Confused with IBS?
Type 2 BAM is the type that causes the most diagnostic confusion because there is no obvious cause. There is no ileal disease, no prior surgery, and no clear secondary condition. The patient presents with chronic diarrhea, meets Rome criteria for IBS-D, and conventional testing (bloodwork, colonoscopy, celiac screen) comes back normal. Without specific BAM testing, there is no way to distinguish Type 2 BAM from IBS-D based on standard workup alone. The FGF19 hypothesis helps explain this: the problem is biochemical (bile acid overproduction from impaired feedback signaling), not structural. It will not show up on imaging, endoscopy, or routine blood panels. You have to look for it specifically, and most gastroenterologists, particularly in the United States where SeHCAT is unavailable, do not routinely include BAM in their differential diagnosis for IBS-D.
How Is BAM Diagnosed?
The gold standard test is the SeHCAT scan, available in the UK and parts of Europe. SeHCAT uses a radiolabeled synthetic bile acid (selenium-75-homocholic acid taurine) that you swallow as a capsule. A gamma camera measures how much is retained in your body at day 7. Normal retention is above 15 percent. Retention below 15 percent indicates BAM: below 10 percent is moderate, and below 5 percent is severe. The test is simple, non-invasive, and highly accurate. In the United States, where SeHCAT is not available, the main alternatives are serum C4 (7-alpha-hydroxy-4-cholesten-3-one), a blood marker of bile acid synthesis that is elevated in BAM, and a therapeutic trial of bile acid sequestrants. The C4 test has reasonable sensitivity but can produce false results if the patient is on statins or has liver disease. Many clinicians prefer a therapeutic trial: if the patient responds dramatically to cholestyramine or colesevelam, that is treated as a functional confirmation of BAM.
What Helps: Treatment Options for BAM
Treatment centers on bile acid sequestrants, medications that bind excess bile acids in the intestine and prevent them from reaching the colon. Cholestyramine is the oldest and most studied option, typically started at 4 grams once daily and increased as needed up to 4 grams three times daily. Colesevelam is a newer alternative that comes in tablet form and is generally better tolerated. Colestipol is a third option used less frequently. Response rates are 70 to 80 percent in patients with confirmed BAM on SeHCAT. Many patients notice improvement within the first few days. Tracking your symptoms and stool patterns during a treatment trial can help you and your doctor determine whether the response is meaningful. The GLP1Gut app can be useful for logging daily stool frequency, consistency, and timing relative to starting treatment.
Dietary modifications also help. Reducing fat intake decreases the amount of bile acids released, which reduces the volume reaching the colon. This is not a permanent restriction but a practical tool for managing symptoms, particularly while optimizing sequestrant dosing. Eating smaller, more frequent meals rather than large fatty meals can also reduce symptom spikes.
What Should You Do Next?
If you have been diagnosed with IBS-D and your symptoms have not responded adequately to dietary changes, antispasmodics, or low-FODMAP approaches, ask your gastroenterologist about BAM testing. Specifically, request a serum C4 level (if available in your area) or discuss a therapeutic trial of a bile acid sequestrant. If your symptoms started or worsened after gallbladder removal, bring up Type 3 BAM explicitly. The 25 to 30 percent statistic means this is not a rare zebra diagnosis. It is a common, treatable condition that is simply undertested.
Can you have both IBS-D and BAM at the same time?
Yes. Some patients have visceral hypersensitivity (a hallmark of IBS) alongside bile acid overproduction. In these cases, treating BAM with a sequestrant may improve but not completely resolve symptoms, because the functional IBS component remains. The practical approach is to treat BAM first, see how much improvement you get, and then address any residual symptoms with IBS-specific strategies.
Does everyone who has their gallbladder removed develop BAM?
No. Estimates suggest 10 to 20 percent of post-cholecystectomy patients develop clinically significant diarrhea from bile acid malabsorption. The gallbladder normally stores and concentrates bile between meals. Without it, bile flows continuously into the small intestine, and some patients cannot reabsorb the increased bile acid load. If diarrhea developed within weeks to months of surgery and has persisted, post-cholecystectomy BAM is a strong possibility.
Is BAM a lifelong condition?
It depends on the type. Type 1 BAM from ileal resection is typically permanent unless the underlying disease (like Crohn's) goes into deep remission and ileal function recovers. Type 2 (idiopathic) BAM appears to be chronic in most cases, though long-term natural history data are limited. Type 3 BAM from cholecystectomy is usually permanent, as the gallbladder does not regenerate. The good news is that bile acid sequestrants remain effective long-term for most patients.
What is FGF19 and why does it matter for BAM?
FGF19 (fibroblast growth factor 19) is a hormone produced by cells in the terminal ileum when bile acids are reabsorbed. It travels to the liver and signals it to reduce bile acid production. In Type 2 BAM, FGF19 levels are often low, which means the liver never gets the 'stop producing' signal. The result is bile acid overproduction. This discovery shifted the understanding of Type 2 BAM from a problem of poor absorption to a problem of overproduction. FGF19 analogs are being researched as potential future treatments.
Why is SeHCAT not available in the United States?
SeHCAT has never received FDA approval for use in the United States. The reasons are primarily commercial and regulatory rather than scientific. The test is well-validated and widely used in the UK and parts of Europe. In the US, clinicians rely on serum C4 testing and therapeutic trials as alternatives. Several gastroenterology societies have called for improved BAM testing access in the US, but as of 2026, SeHCAT remains unavailable.
âšī¸This article is for informational purposes only and does not constitute medical advice. Chronic diarrhea has many potential causes including inflammatory bowel disease, celiac disease, infections, and malignancies. Always consult a qualified healthcare provider for proper diagnosis and treatment.